# Case Study: Defending Against a Hostile Takeover

## Executive Summary

MedDevice Corporation, a profitable medical device company, has received an unsolicited acquisition proposal from GlobalHealth Industries. The board has 15 days to respond. As an advisor to MedDevice's special committee, you must evaluate the offer, assess defense options, and recommend a course of action.

**Key Decision:** How should MedDevice's board respond to GlobalHealth's hostile bid?

---

## Background

### MedDevice Corporation (Target)

**Company Overview:**
- Founded: 1998, headquartered in Minneapolis
- Business: Surgical instruments and implantable devices
- Revenue: $800M (2024)
- EBITDA: $160M (20% margin)
- Net Income: $100M
- Employees: 3,500
- Market position: #3 in core markets

**Stock Information:**
- Stock price (pre-announcement): $50/share
- Shares outstanding: 60M
- Market cap: $3.0B
- 52-week range: $42-$58

**Corporate Governance:**
- Staggered board (3 classes, 3-year terms)
- Poison pill (15% trigger, 5-year duration)
- No supermajority voting requirements
- 7 board members (5 independent)

**Ownership Structure:**
| Shareholder | Ownership |
|-------------|-----------|
| Institutional investors | 65% |
| Index funds | 20% |
| Management/Board | 8% |
| Retail | 7% |

### GlobalHealth Industries (Acquirer)

**Company Overview:**
- Fortune 500 healthcare conglomerate
- Revenue: $25B
- Market cap: $80B
- Diversified across pharma, devices, diagnostics
- Serial acquirer (10+ deals in last 5 years)
- Strong balance sheet

**Strategic Interest:**
- Seeking growth through M&A
- Medical devices is priority segment
- MedDevice would be largest device acquisition
- Significant synergy potential claimed

---

## Exhibit 1: The Hostile Offer

### Bear Hug Letter (Received March 1)

```
Dear Members of the Board:

GlobalHealth Industries hereby proposes to acquire all
outstanding shares of MedDevice Corporation for $65 per
share in cash, representing:

- 30% premium to current stock price
- 20% premium to 52-week high
- 35% premium to 90-day VWAP

This proposal is not subject to any financing contingency.
GlobalHealth has committed financing from JPMorgan Chase
and Bank of America for the full transaction value.

We believe this offer provides compelling, certain value
to MedDevice shareholders. We have attempted to engage
constructively with management over the past six months
but have been rebuffed.

We are prepared to commence a tender offer and proxy
contest if the Board does not engage within 15 days.

Sincerely,
John Richardson
CEO, GlobalHealth Industries
```

### Offer Details

```
Offer Price: $65/share
Form: 100% cash
Financing: Fully committed
Conditions:
- Minimum tender: 50.1%
- HSR clearance
- No material adverse change
- Poison pill redemption

Premium Analysis:
- Current price: $50
- Offer: $65
- Premium: 30%

Total Transaction Value:
$65 Ã— 60M shares = $3.9B
```

---

## Exhibit 2: MedDevice Financial Analysis

### Historical Performance ($M)

| Item | 2022 | 2023 | 2024 | 2025E | 2026E |
|------|------|------|------|-------|-------|
| Revenue | 680 | 740 | 800 | 880 | 968 |
| Growth | 10% | 9% | 8% | 10% | 10% |
| EBITDA | 129 | 148 | 160 | 185 | 213 |
| Margin | 19% | 20% | 20% | 21% | 22% |
| Net Income | 75 | 88 | 100 | 120 | 145 |
| EPS | $1.25 | $1.47 | $1.67 | $2.00 | $2.42 |

### Management's Strategic Plan

**"Vision 2028" - Presented to Board February**

```
Revenue Targets:
- 2024: $800M (actual)
- 2026: $1,000M (25% growth)
- 2028: $1,300M (63% growth from 2024)

EBITDA Margin Expansion:
- 2024: 20%
- 2026: 23%
- 2028: 25%

Key Initiatives:
1. New product launches (3 major devices)
2. Geographic expansion (Asia-Pacific)
3. Operational excellence program
4. Strategic tuck-in acquisitions

Investment Required: $150M over 4 years
```

### Valuation Analysis

**DCF Valuation (Management Case):**
```
Assumptions:
- Revenue CAGR: 13% (through 2028)
- Terminal growth: 3%
- WACC: 9%

Results:
- Enterprise Value: $4.8B
- Net Debt: $200M
- Equity Value: $4.6B
- Per Share: $77
```

**Trading Comparables:**

| Company | EV/Revenue | EV/EBITDA |
|---------|------------|-----------|
| Peer A | 3.8x | 18.0x |
| Peer B | 4.2x | 19.5x |
| Peer C | 3.5x | 17.5x |
| Peer D | 4.5x | 21.0x |
| **Median** | **4.0x** | **18.8x** |
| MedDevice at $50 | 3.8x | 18.8x |
| MedDevice at $65 | 4.9x | 24.4x |

**Precedent Transactions:**

| Target | EV/Revenue | EV/EBITDA | Premium |
|--------|------------|-----------|---------|
| DeviceCo | 4.5x | 22.0x | 35% |
| MedTech Inc | 5.0x | 25.0x | 40% |
| SurgicalSys | 4.2x | 21.0x | 28% |
| **Median** | **4.5x** | **22.0x** | **35%** |
| GlobalHealth Offer | 4.9x | 24.4x | 30% |

---

## Exhibit 3: GlobalHealth's Position

### Public Statements

**Press Release (March 1):**
```
"MedDevice is an exceptional company with strong products
and talented employees. We believe a combination with
GlobalHealth would create significant value through:

- Expanded global distribution
- R&D synergies
- Operational efficiencies
- Strategic alignment

Our offer of $65 per share represents a compelling premium.
We hope the MedDevice board will engage constructively."
```

### Analyst Estimates of Synergies

```
GlobalHealth Claimed Synergies:
- Cost synergies: $80M (by Year 3)
- Revenue synergies: $100M (by Year 5)

Independent Analyst Estimates:
- Cost synergies: $50-60M (achievable)
- Revenue synergies: $30-50M (uncertain)

Implied Synergy Value (at 8x):
- Low: $400M
- High: $720M
- Midpoint: $560M
```

### Financial Capacity

```
GlobalHealth Balance Sheet:
- Cash: $8B
- Debt capacity: $15B additional
- Current leverage: 1.5x EBITDA

Transaction Financing:
- Committed bank facilities: $4.5B
- No financing contingency
- Expected close: 4-6 months post-announcement
```

---

## Exhibit 4: Defense Options

### Available Defenses

**1. Poison Pill (In Place)**
```
Current Terms:
- Trigger: 15% ownership
- Exercise: 50% discount
- Duration: 5 years (3 years remaining)

Effect: Prevents hostile accumulation above 15%
Limitation: Can be removed by shareholder vote
```

**2. Staggered Board**
```
Current Structure:
- 3 classes, 3-year terms
- Next election: Annual meeting (May)
- 2 directors up for election

Effect: Full board control requires 2 elections (2+ years)
Limitation: Combined with pill, delays but doesn't prevent
```

**3. "Just Say No" Defense**
```
Approach: Maintain defenses, refuse to negotiate
Basis: Board believes company worth more
Requirement: Good faith belief offer inadequate

Risk: Shareholder pressure, proxy fight
```

**4. White Knight**
```
Approach: Find friendly alternative buyer
Candidates:
- Johnson & Johnson (prior interest rumored)
- Medtronic (strategic fit)
- Private equity consortium

Challenge: Finding higher bid
```

**5. Recapitalization**
```
Approach: Special dividend or buyback
Structure: $20/share dividend + value remaining
Effect: Delivers value without sale

Challenge: Leverage implications, doesn't maximize value
```

---

## Exhibit 5: Stakeholder Positions

### Shareholder Communications Received

**Apex Capital (12% holder):**
```
"The GlobalHealth offer deserves serious consideration.
A 30% premium is attractive. We expect the board to
engage constructively and run a fair process."
```

**ValueFirst Partners (8% holder):**
```
"We have long believed MedDevice is undervalued. The
management plan presented in February is compelling.
We support the board in exploring all alternatives
but believe standalone value exceeds $65."
```

**Governance Advisory Firm (ISS):**
```
"The board should not maintain the poison pill
indefinitely in the face of a premium all-cash offer.
Shareholders should have the opportunity to decide."
```

### Employee Concerns

```
Key Issues Raised:
- Job security in acquisition
- Minneapolis HQ future
- Management retention
- Cultural integration

Current Sentiment:
- Senior management: Opposed to deal
- Middle management: Uncertain
- Union (200 employees): Seeking assurances
```

---

## Exhibit 6: Legal Considerations

### Fiduciary Duties

**Delaware Law Applies:**

```
Business Judgment Rule:
- Directors presumed to act in good faith
- Must be informed
- Must act in best interest of corporation

Unocal Standard (Defensive Measures):
- Reasonable grounds to believe threat exists
- Response proportionate to threat
- Defense cannot be preclusive or coercive

Revlon Duties (If "For Sale"):
- Maximize shareholder value
- Run fair auction process
- Cannot favor one bidder unreasonably
```

### Legal Counsel Advice

```
"The board may maintain the poison pill while
evaluating the offer and alternatives. However,
the pill cannot be maintained indefinitely in the
face of a premium all-cash offer without
substantial justification.

If the board determines the company is 'for sale,'
Revlon duties apply and the board must seek to
maximize value for shareholders.

We recommend forming a special committee of
independent directors to evaluate the offer
and oversee the process."
```

---

## Analysis Questions

### Part A: Offer Evaluation (25 points)

1. **Valuation Assessment**
   - Is $65/share a fair price for MedDevice?
   - How does it compare to DCF, trading comps, and precedents?
   - What's the implied value with synergies?

2. **Premium Analysis**
   - Is a 30% premium adequate?
   - What premium should shareholders expect?

### Part B: Defense Analysis (25 points)

1. **Defense Evaluation**
   - What defenses are available and effective?
   - How long can the board maintain the pill?
   - What are the legal constraints?

2. **Defense Strategy**
   - Which defense approach do you recommend?
   - What are the risks of each approach?

### Part C: Alternatives Assessment (25 points)

1. **Standalone Value**
   - Is management's Vision 2028 plan credible?
   - What's the probability-weighted standalone value?

2. **White Knight Potential**
   - Should the board seek alternative buyers?
   - What price could a white knight offer?

### Part D: Recommendation (25 points)

1. **Board Response**
   - What should the board's response be?
   - What statement should be issued?

2. **Process Design**
   - How should the board proceed over the next 90 days?
   - What milestones and decision points?

3. **Negotiation Strategy**
   - If engaging with GlobalHealth, what terms should be sought?
   - What's the minimum acceptable price?

---

## Teaching Note

### Learning Objectives
This case teaches students to:
- Evaluate hostile takeover offers from target perspective
- Understand fiduciary duties and legal constraints
- Design appropriate defense strategies
- Balance stakeholder interests in contested situations

### Key Insights

**Offer Analysis:**
- $65/share is at/above trading comps (4.9x vs 4.0x)
- Below precedent transactions median (4.9x vs 4.5x on revenue, but 24.4x vs 22.0x on EBITDA)
- 30% premium is at low end for hostile deals
- With synergies, GlobalHealth could pay $75-80

**Defense Options:**
- Pill + staggered board provide time, not permanent defense
- "Just say no" only works if standalone value is credible
- White knight may emerge if genuine process run
- Revlon duties likely triggered by any engagement

**Stakeholder Considerations:**
- Institutional shareholders want fair process
- Some activists support management
- Employees have legitimate concerns
- Legal exposure if board appears entrenched

### Recommended Approach

**Phase 1 (Days 1-15): Initial Response**
```
Actions:
1. Form special committee (3 independent directors)
2. Engage independent advisors
3. Issue "evaluating" press release
4. Do NOT reject outright
5. Prepare detailed valuation analysis

Statement:
"The Board has formed a Special Committee to
carefully evaluate the proposal in the context of
MedDevice's strategic plan and all alternatives.
Shareholders need take no action at this time."
```

**Phase 2 (Days 16-60): Process**
```
Actions:
1. Complete standalone valuation
2. Approach 3-4 potential white knights
3. Consider negotiation with GlobalHealth
4. Prepare proxy defense materials
5. Regular shareholder communication

Key Question: Is Vision 2028 credible enough to decline?
```

**Phase 3 (Days 61-90): Resolution**
```
Outcomes:
A) Higher offer secured (GlobalHealth or white knight)
B) Negotiate improved GlobalHealth offer ($70-75)
C) Standalone with enhanced shareholder returns
D) Recommend GlobalHealth offer if best available

Recommended: Seek improved offer or white knight
Target Price: $72-75/share
Walk-Away: Standalone if offers below $70
```

### Valuation Summary

```
Methodology          | Value Per Share
---------------------|------------------
Current Trading      | $50
GlobalHealth Offer   | $65
Trading Comps        | $55-60
Precedent Trans      | $65-75
DCF (Management)     | $77
DCF (Conservative)   | $65-70

With Synergies:
GlobalHealth Value   | $75-85
White Knight Value   | $70-80

Conclusion: $65 is low end of fair value
Target: $72-75
Minimum: $68-70
```

### Discussion Questions

1. Does the 30% premium obligate the board to accept? What premium would?

2. How much weight should the board give to management's strategic plan versus current market value?

3. If employees would lose jobs in acquisition, how should that factor into the board's decision?

4. What if no white knight emerges and GlobalHealth won't raise its offer?

### Key Takeaways

1. **Process matters** - Fair, informed process protects board
2. **Fiduciary duties are real** - Can't "just say no" indefinitely
3. **Alternatives must be explored** - White knight, standalone
4. **Stakeholder management** - Shareholders ultimately decide
5. **Timing is strategic** - Use defensive tools to create time
6. **Documentation critical** - Record deliberations carefully
